Y Mabs Therapeutics Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2025 to a ratio of 4.64, this is below the company average, and notable indication of worsening business environment. Average receivable collection period, for the Y Mabs Therapeutics Inc in Jun 30 2025 quarter, has decreased to 79 days, compared to 82 days, in the Mar 31 2025 quarter.

If we take a look into Healthcare sector 374 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2025 from 2212 to 2695.

What is Receivable Turnover Ratio?
What is Y Mabs Therapeutics Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

YMAB Receivables Turnover Ratio	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Receivable Change	-29.07 %	-13.83 %	-12.32 %	5.52 %	16.07 %
Y / Y Revenue Change	-17.26 %	4.88 %	13.4 %	-9.74 %	9.86 %
Receivable Turnover Ratio (TTM)	4.64	4.46	4.26	3.97	4.12
YMAB's Total Ranking	# 2695	# 2212	# 1490	# 1351	# 2519
Accounts Receivable average collection period days	79	82	86	92	89
Seq. Receivable Change	-11.27 %	-9.89 %	-1.14 %	-10.25 %	7.79 %
Seq. Revenue Change	-9.76 %	-21.1 %	43.51 %	-19.02 %	14.38 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 110
Healthcare Sector	# 375
Overall Market	# 2695

Receivable Turnover Ratio Statistics
High	Average	Low
6.81	4.78	3.35
(Dec 31 2022)		(Sep 30 2024)

YMAB Company Profile • Back to YMAB Efficiency Comparisons • Compare YMAB Receivables Turnover Ratio to its Competitors

Financial Statements
Y Mabs Therapeutics Inc 's Accounts Receivable	$ 16 Millions	Visit YMAB's Balance sheet
Y Mabs Therapeutics Inc 's Sales TTM	$ 85 Millions	Visit YMAB's Income Statement
Sources of YMAB's Revenues		Visit YMAB's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
YMAB's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
YMAB's Growth Rates	YMAB's Roa	YMAB's Inventory Turnover Ratio	YMAB's Dividend Comparisons
YMAB's Profitability Ratios	YMAB's Roi	YMAB's Asset Turnover Ratio	YMAB's Dividend Growth
YMAB's Valuation Ratios	YMAB's Roe	YMAB's Financial Strength Ratios	YMAB's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2025, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2025	Receivable at quarter ending Jun 30 2025
Ethema Health Corporation	14.53	$ 11.650 Millions	$ 0.802 Millions
Amneal Pharmaceuticals Inc	14.50	$ 2,851.220 Millions	$ 196.597 Millions
Inmed Pharmaceuticals Inc	14.32	$ 4.943 Millions	$ 0.345 Millions
Mannkind Corporation	14.03	$ 301.736 Millions	$ 21.508 Millions
Icu Medical Inc	13.41	$ 2,371.547 Millions	$ 176.808 Millions
China Pharma Holdings Inc	13.25	$ 4.396 Millions	$ 0.332 Millions
Sangamo Therapeutics Inc	13.24	$ 81.706 Millions	$ 6.170 Millions
Qhslab Inc	13.13	$ 2.421 Millions	$ 0.184 Millions
Protalix Biotherapeutics inc	12.89	$ 61.948 Millions	$ 4.805 Millions
Ptc Therapeutics inc	12.73	$ 1,764.929 Millions	$ 138.666 Millions
Cytokinetics Incorporated	12.55	$ 85.738 Millions	$ 6.829 Millions
Day One Biopharmaceuticals Inc	12.45	$ 187.638 Millions	$ 15.074 Millions
Rosecliff Acquisition Corp I	12.45	$ 28.320 Millions	$ 2.275 Millions
Chemed Corporation	11.98	$ 2,511.915 Millions	$ 209.599 Millions
Option Care Health Inc	11.97	$ 5,375.352 Millions	$ 449.147 Millions
Corcept Therapeutics Inc	11.93	$ 716.080 Millions	$ 60.020 Millions
Nrc Health	11.89	$ 140.315 Millions	$ 11.805 Millions
Teladoc Health Inc	11.50	$ 2,542.268 Millions	$ 221.147 Millions
Sutro Biopharma Inc	11.35	$ 104.473 Millions	$ 9.208 Millions
Tandem Diabetes Care Inc	11.30	$ 1,001.193 Millions	$ 88.607 Millions
Sanuwave Health Inc	11.30	$ 39.192 Millions	$ 3.470 Millions
Harvard Apparatus Regenerative Technology Inc	11.27	$ 0.679 Millions	$ 0.060 Millions
Integrated Biopharma Inc	11.20	$ 53.562 Millions	$ 4.781 Millions
Lifeloc Technologies Inc	11.00	$ 8.494 Millions	$ 0.772 Millions
Nexgel Inc	10.86	$ 9.518 Millions	$ 0.877 Millions
Immunocore Holdings Plc	10.82	$ 356.145 Millions	$ 32.912 Millions
Ss Innovations International Inc	10.80	$ 32.503 Millions	$ 3.010 Millions
Skinhealth Systems Inc	10.70	$ 309.687 Millions	$ 28.949 Millions
Travere Therapeutics Inc	10.65	$ 333.866 Millions	$ 31.346 Millions
National Healthcare Corp	10.61	$ 1,458.155 Millions	$ 137.376 Millions

Date modified: 2026-08-29T17:41:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.